Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2020

Feb 14, 2020

30291_dirs_2020-02-14_05fa7e05-6d97-4836-8102-5a80b4dc6397.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2020-02-12

Reporting Person: Galdes Alphonse (EVP Pharmaceutical Oper & Tech)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-02-12 Common Stock M 484 Acquired 1912.264 Direct
2020-02-12 Common Stock F 153 $331.76 Disposed 1759.264 Direct
2020-02-12 Common Stock M 312 Acquired 2071.264 Direct
2020-02-12 Common Stock F 92 $331.76 Disposed 1979.264 Direct
2020-02-12 Common Stock M 358 Acquired 2337.264 Direct
2020-02-12 Common Stock F 106 $331.76 Disposed 2231.264 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-02-12 Restricted Stock Unit $0 A 6780 Acquired 2023-02-12 Common Stock (6780) Direct
2020-02-12 Restricted Stock Unit $0 M 484 Disposed 2020-02-12 Common Stock (484) Direct
2020-02-12 Restricted Stock Unit $0 M 312 Disposed 2021-02-12 Common Stock (312) Direct
2020-02-12 Restricted Stock Unit $0 J 294 Disposed 2021-02-12 Common Stock (294) Direct
2020-02-12 Restricted Stock Unit $0 M 358 Disposed 2022-02-12 Common Stock (358) Direct
2020-02-12 Restricted Stock Unit $0 J 420 Disposed 2022-02-12 Common Stock (420) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 969.366 Indirect

Footnotes

F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

F2: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date.

F3: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.